SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SSgA Active Trust - State Street SPDR S&P 500 ETF Trust

SPY is experiencing significant volatility driven by escalating Middle East tensions, fueling community debate between fears of a broader market correction from rising oil prices and inflation, and conviction that the dip presents a buying opportunity.

Battalion Oil Corp. engages in the acquisition, production, exploration, and development of liquids-rich oil and natural gas assets in the Delaware Basin. The company was founded in 1987 and is headquartered in Houston, TX.

Battalion Oil Corp - Ordinary Shares (New)

Battalion Oil Corp is experiencing a parabolic surge driven by escalating Middle East geopolitical tensions impacting global oil and natural gas prices, with community discussion highlighting significant short interest fueling its explosive upward momentum. Investors are actively debating whether to hold for further gains or take profits amid high volatility, as many see it as a high-risk, high-reward energy play.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

Escalating geopolitical tensions in the Middle East, especially around the Strait of Hormuz and its potential impact on oil prices, are driving significant volatility for QQQ. The community is sharply divided, with some anticipating a deeper market correction while others point to resilient 'buy the dip' behavior and perceived market manipulation.

BlackRock Institutional Trust Company N.A. - iShares Silver Trust

iShares Silver Trust

Amidst escalating geopolitical tensions, iShares Silver Trust ($SLV) is experiencing a sharp selloff, leading to intense community debate about its 'safe haven' status and widespread accusations of market manipulation. Many investors are seeing the dip as a significant buying opportunity, citing underlying physical supply shortages and robust industrial demand from the AI sector as bullish long-term drivers.

Indonesia Energy Corp. Ltd. operates as an oil and gas, exploration, and production company. It engages in oil and gas assets portfolio with a mix between medium-sized producing blocks and exploration blocks with significant resources. Its portfolio includes Kruh, Citarum, and Rangkas Area. The company was founded by James J. Huang and Wirawan Jusuf in 2014 and is headquartered in Jakarta, Indonesia.

Indonesia Energy Corp Ltd

Escalating geopolitical tensions surrounding the Iran conflict and rising crude oil prices, exacerbated by reports of the Strait of Hormuz closure, are driving conversation around Indonesia Energy Corp Ltd (INDO). The community anticipates a significant short squeeze and a major run, similar to other surging energy stocks, as traders rotate profits into INDO.

SPDR Gold Trust - SPDR Gold Shares

SPDR Gold Shares ETF

GLD is trending due to surging safe-haven demand amidst escalating Middle East tensions and concerns over global stability, with the community actively debating if this marks a sustained gold rally or a temporary geopolitical spike.

Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company, which focuses on the discovery, acquisition, and development of small molecules and biologics to treat and prevent human disease and alleviate suffering. Its portfolio includes TNX-102 SL, TNX-601, TNX-801, and TNX-1800. The company was founded by Seth Lederman and Donald W. Landry on November 16, 2007 and is headquartered in Berkeley Heights, NJ.

Tonix Pharmaceuticals Holding Corp

Tonix Pharmaceuticals is trending following its uplisting to the Nasdaq Global Select Market and reports of accelerating sales and expanding formulary coverage for its fibromyalgia drug, Tonmya. The community sees this as a de-risking milestone, fueling discussions on potential for a significant re-rating and short squeeze, as bullish investors highlight strong institutional accumulation against concerns of past dilution.

Sea Ltd. is an internet and mobile platform company, which engages in the provision of online gaming services. It operates through the following segments: Digital Entertainment, E-Commerce, and Digital Financial Services. The Digital Entertainment segment offers and develops mobile and PC online games. The E-Commerce segment manages a third-party marketplace through the Shopee mobile app and websites that connect buyers and sellers. The Digital Financial Services segment includes a variety of payment services and loans to individuals and businesses through SeaMoney. Sea was founded by Xiao Dong Li, Gang Ye, and Jing Ye Chen on May 8, 2009 and is headquartered in Singapore.

Sea Ltd - ADR

Sea Ltd is trending after its Q4 earnings revealed robust revenue growth and optimistic 2026 Shopee GMV guidance, even as an EPS miss fuels community debate on whether strategic investments can overcome ongoing margin pressures and intense competition from rivals like TikTok Shop.

Gorilla Technology Group, Inc. engages in the provision of video intelligence, Internet of Things (IoT) security, edge AI data analytics, and operational technology security solutions and services in Asia Pacific. It operates through the following segments: Video IoT, Security Convergence, and Other. The company was founded by Spincer Koh in May 2001 and is headquartered in London, the United Kingdom.

Gorilla Technology Group Inc

Gorilla Technology Group Inc. is trending after reporting record-breaking full-year 2025 revenue and significant profitability improvements, backed by a multi-billion dollar AI infrastructure pipeline and strong cash reserves. Despite these positive fundamentals, the community is sharply divided, with many bulls expressing frustration over the stock's persistent undervaluation while skeptics question financial transparency and the lack of corresponding price appreciation.

Credo Technology Group Holding Ltd. engages in the development of connectivity solutions and products for the data infrastructure market. Its products include integrated circuits, active electrical cables, and SerDes chiplets. The company was founded by Chi Fung Cheng and Yat Tung Lam on 2008 and is headquartered in George Town, Cayman Islands.

Credo Technology Group Holding Ltd

Credo Technology Group is trending due to a sharp market reaction to its latest earnings report; despite beating Q3 expectations, conservative Q4 guidance has sparked community debate regarding its valuation and the high growth demands within the AI infrastructure sector.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>SENTI-202, the immune cell therapy cancer treatment, received a Regenerative Medicine Advanced Therapy (RMAT) designation that would make it eligible for quicker reviews.</li><li>This is the second FDA designation for the treatment this year.&nbsp;</li><li>On Stocktwits, retail sentiment for the stock rose to ‘extremely bullish’ territory while message volume jumped to ‘extremely high’ levels at the time of writing. &nbsp;</li></ul>Shares of Senti Biosciences, Inc. (SNTI) surged over 20% on Tuesday’s premarket trading after the company announced positive news around its cancer treatment.&nbsp;The clinical-stage biotech company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://investors.sentibio.com/news-releases/news-release-details/senti-bio-announces-updated-senti-202-clinical-data-ongoing">announced</a> in a press release that the U.S. Food and Drug Administration (FDA) gave SENTI-202, an immune cell therapy cancer treatment, a Regenerative Medicine Advanced Therapy (RMAT) designation.&nbsp;<h2 class="st-heading-2">What Does This Mean?</h2>The RMAT designation from the FDA for the company’s cancer treatment indicates an expedited development and review, providing benefits similar to the FDA’s Breakthrough Therapy and the Fast Track programs such as higher interactions with the Agency through the development process as well as eligibility for quicker and even priority reviews.“This significant FDA designation validates both the tremendous need for better treatments for R/R AML and the promise of SENTI-202 to transform the therapeutic landscape for this notoriously aggressive cancer,” said Timothy Lu, Co-Founder and CEO of Senti Biosciences, in the press release. “We are incredibly pleased with the exciting clinical progress we recently shared at the ASH conference on SENTI-202.”Data from its ongoing trial showed a 50% overall response rate and 42% complete remission at the recommended Phase 2 dose, the company revealed. Earlier this year, the U.S. FDA granted the treatment Orphan Drug Designation.&nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around&nbsp;<a href="https://stocktwits.com/symbol/SNTI">SNTI</a> jumped from ‘neutral’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:1284/149;" src="https://news.stocktwits-cdn.com/Screenshot_2025_12_09_at_7_13_22_PM_png_c037e194c0.webp" alt="On Stocktwits, retail sentiment around&nbsp;SNTI jumped from ‘neutral’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘extremely high’ levels." width="1284" height="149"></figure>One user on the platform predicted that STNI’s share price could go up to $5. The stock was trading around $2.85 at the time of writing.&nbsp;<stembedurl>https://stocktwits.com/Stratsys/message/638587949</stembedurl>Shares of SNTI have fallen over 37% year to date.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com

In this photo illustration, a medicine pill is seen in a hand dressed in a medical glove with the U.S. FDA logo in the background. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images) 

SNTI Shares Surge Over 20% In Pre-Market Trade After FDA RMAT Designation For Cancer Treatment

Senti Biopharma shares rallied in premarket trading on Tuesday after its cancer treatment received a positive designation from the U.S. FDA.

SNTI Shares Surge Over 20% In Pre-Market Trade After FDA RMAT Designation For Cancer Treatment 

Equity

Shares of Senti Biosciences Inc. skyrocketed over 400% on Monday afternoon, making it the top gainer across U.S. stock exchanges and the top trending ticker on Stocktwits.&nbsp;The surge was fueled by the biotech company’s announcement of an oversubscribed private placement and promising early clinical data for its experimental blood cancer treatment.&nbsp;The stock rallied to levels last seen in April 2023, drawing significant attention from retail investors.Senti disclosed that it had entered into a securities purchase agreement with existing and new accredited investors to raise approximately $37.6 million through the sale of Series A&nbsp;convertible preferred stock in a private investment in public equity (PIPE) financing.&nbsp;The deal includes warrants allowing investors to purchase up to an additional 25,069,500 shares of the company’s common stock, contingent on shareholder approval.&nbsp;Additionally, an option was granted to a specific investor to buy 4,444 more shares of preferred stock and accompanying warrants, potentially generating $10 million more in gross proceeds by Dec. 27.The PIPE financing, led by Celadon Partners and supported by institutional players like New Enterprise Associates, Leaps by Bayer, and Nantahala Capital, is expected to close by Thursday.&nbsp;Senti plans to use the proceeds to advance its SENTI-202 program, scale manufacturing capabilities, support ongoing R&amp;D efforts, and for general corporate purposes.Positive clinical data from the Phase 1 trial of SENTI-202 also contributed to the stock’s meteoric rise.&nbsp;The trial focused on treating acute myeloid leukemia and other relapsed or refractory hematologic cancers using Senti’s proprietary gene circuit technology.&nbsp;Initial results revealed that two of three treated patients achieved complete remission, confirmed by bone marrow biopsy, with both patients remaining in remission for three and four months, respectively.&nbsp;The treatment was reported to have a generally well-tolerated safety profile at the administered dose, with further trial updates expected next year as dose escalation continues.<figure class="image"><a href="https://stocktwits.com/symbol/SNTI"><img style="aspect-ratio:1314/320;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/SNTI_sentiment_meter_and_message_volume_on_Dec_2_42660f4d88.png" alt="SNTI sentiment meter and message volume on Dec 2.png" width="1314" height="320"></a><figcaption>SNTI sentiment meter and message volume on Dec 2 as of 1:00 pm ET | source: Stocktwits</figcaption></figure>On Stocktwits, retail sentiment for SNTI turned ‘extremely bullish’ amid soaring message volume.<stembedurl>https://stocktwits.com/DJTAZ/message/594734529</stembedurl><stembedurl>https://stocktwits.com/Pianomemo/message/594734011</stembedurl>Year-to-date, Senti Biosciences shares have gained over 70%, with Monday’s explosive rally marking a pivotal moment for the company’s visibility in the biotech sector.For updates and corrections email newsroom[at]stocktwits[dot]com.Read next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/tsla-stock-rises-after-upgrade-price-target-hikes/cJ9kq43RhE">Tesla Stock Rises After Massive Price Target Hikes On Trump, AI Factors: Retail’s Charged Up</a>

Senti's deal includes warrants allowing investors to purchase up to an additional 25,069,500 shares of the company’s common stock

Senti Biosciences Skyrockets 400% On Oversubscribed PIPE Deal, Promising Cancer Trial Data: Retail Overjoyed

The stock rallied to levels last seen in April 2023, drawing significant attention from retail investors.

This account has been verified as an official SNTI representative.

Verified Account

Senti Biosciences

Senti Biosciences, Inc. is a biotechnology company. It engages in the business of developing next-generation cell and gene therapies engineered with a gene circuit platform technology to fight challenging diseases. The company was founded by Timothy K. Lu, Wilson Wong, and Philip Lee on June 9, 2016 and is headquartered in South San Francisco, CA.

Senti Biosciences Inc.

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

What do you expect from $MDB earnings today?

Current Price	$0.9309
Prev Close	$0.9439
Open	$0.90
Dividend Yield	0.00%
50-Day Moving Average	$1.03
Beta	1.22
Avg. Volume	281,302.45
PE Ratio	-0.28

52-Week High	$5.10
52-Week Low	$0.797
Market Capitalization	$24.82M
EPS (Annual)	-$12.04
Price to Book	3.06
Revenue Per Employee	$0.00

SNTI
Senti Biosciences Inc.

Feed

News

Sentiment

Fundamentals

Info

Latest SNTI News

SNTISenti Biosciences Inc.